ArticleCureus2024
A Decade of Prevalence and Clinicopathological Insights Into Classical Hodgkin Lymphoma: A Study From an Indonesian Tertiary Hospital.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Classical Hodgkin lymphoma (cHL) is a lymphoid malignancy originating from germinal center B cells, predominantly affecting young adults. The clinical profile, histologic subtypes, and immunohistochemical (IHC) patterns play crucial roles in diagnosing cHL and predicting prognosis. This study examines the prevalence, clinicopathological features, and IHC patterns of cHL at Dr. Cipto Mangunkusumo Hospital in Jakarta, Indonesia, based on large-scale data collected over a decade. Methods This retrospective analysis included 739 confirmed cases of cHL from 2014 to 2023, identified using hematoxylin and eosin staining and an IHC panel. Data on patient demographics, tumor locations, and stages were collected from medical records. The IHC markers utilized were CD20, CD3, CD30, CD15, PAX5, MUM1, Ki67, and CD45. Chi-square and Fisher exact tests were employed to analyze the distribution of subtypes across different age groups and stages. Result The most affected age group was 20-29 years, comprising 239 cases (32.34%), with a male predominance of 396 cases (53.59%). The majority of tumors were located in nodal areas, accounting for 532 cases (84.31%), while 99 cases (15.69%) were found in extranodal sites, predominantly in the mediastinum. The nodular sclerosis (NS) subtype was the most frequent, accounting for 461 cases (62.38%), followed by mixed cellularity, lymphocyte-depleted, and lymphocyte-rich classical Hodgkin lymphoma. Most cases were diagnosed at early stages (I-III), with NS significantly associated with early-stage diagnosis (OR 3.06, 95% confidence interval (CI) 1.30-7.22). Conclusion The occurrence of HL in terms of prevalence, age, gender, and stage in our study is similar to other Asian countries. Notable correlations were observed between HL subtypes with age and stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.